irafamdastat

Irafamdastat (BMS-986353) is a small molecule fatty acid amide hydrolase (FAAH) inhibitor developed by Bristol Myers Squibb. FAAH is the primary enzyme responsible for the degradation of anandamide, an endogenous cannabinoid neurotransmitter. By inhibiting FAAH, irafamdastat increases levels of anandamide, which acts as an agonist at cannabinoid receptors (CB1 and CB2), potentially modulating neuroinflammation, pain, and behavioral symptoms. The drug is currently in Phase 2 clinical development for the treatment of agitation associated with Alzheimer's disease and spasticity associated with multiple sclerosis. It aims to provide a non-opioid, non-antipsychotic approach to managing neuropsychiatric and motor symptoms in these populations.

Other names

irafamdastat